polyvalent melanoma vaccine

BIOLOGICAL2 trials

Sponsors

NYU Langone Health, CancerVax Corporation

Conditions

Melanoma (Skin)

Phase 2

Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma

CompletedNCT00004104

NYU Langone HealthMelanoma (Skin)

Start: 1998-06-30Updated: 2016-03-31

Vaccine Therapy in Treating Patients With Malignant Melanoma

CancerVax CorporationMelanoma (Skin)

Start: 2005-07-31Updated: 2013-12-19